Ildstad Suzanne 4/A
4/A · Talaris Therapeutics, Inc. · Filed Apr 7, 2023
Insider Transaction Report
Form 4/AAmended
Ildstad Suzanne
DirectorChief Scientific Officer10% Owner
Transactions
- Sale
Common Stock
2023-03-01$2.05/sh−29$59→ 3,071,366 total
Holdings
- 1,200,000(indirect: by GRAT)
Common Stock
- 654,205(indirect: See footnote)
Common Stock
- 654,205(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]This amendment is being filed solely to indicated the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2022.
- [F2]These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F3]These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.